Expert Opinion on Investigational Drugs 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Insights into the anti-inflammatory and anti-arthritic potential of 3-Acetyl-11-keto- β-Boswellic Acid as a therapeutic approach in Rheumatoid Arthritis
Expert Opin Investig Drugs. 2023 Oct 10:1-5. doi: 10.1080/13543784.2023.2269838. Online ahead of print.NO ABSTRACTPMID:37817458 | DOI:10.1080/13543784.2023.2269838 (Source: Expert Opinion on Investigational Drugs)
Source: Expert Opinion on Investigational Drugs - October 11, 2023 Category: Drugs & Pharmacology Authors: Sakshi Priya Gautam Singhvi Source Type: research
Insights into the anti-inflammatory and anti-arthritic potential of 3-acetyl-11-keto- β-boswellic acid as a therapeutic approach in rheumatoid arthritis
Expert Opin Investig Drugs. 2023 Oct 10. doi: 10.1080/13543784.2023.2269838. Online ahead of print.NO ABSTRACTPMID:37817458 | DOI:10.1080/13543784.2023.2269838 (Source: Expert Opinion on Investigational Drugs)
Source: Expert Opinion on Investigational Drugs - October 11, 2023 Category: Drugs & Pharmacology Authors: Sakshi Priya Gautam Singhvi Source Type: research
MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment
Expert Opin Investig Drugs. 2023 Oct 10:1-6. doi: 10.1080/13543784.2023.2267972. Online ahead of print.ABSTRACTINTRODUCTION: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality worldwide. Lowering LDL-cholesterol, by lifestyle modification or therapeutically, reduces the risk of ASCVD. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein which binds to the LDL-receptor and induces degradation, is a clinically validated target to lower LDL-cholesterol. Injectable PCSK9 inhibitor therapies have demonstrated substantial reductions in LDL-cholesterol with associated decrease...
Source: Expert Opinion on Investigational Drugs - October 10, 2023 Category: Drugs & Pharmacology Authors: John R Burnett Amanda J Hooper Source Type: research
Novel janus-kinase (JAK) inhibitors in myelofibrosis
Expert Opin Investig Drugs. 2023 Oct 9. doi: 10.1080/13543784.2023.2269078. Online ahead of print.ABSTRACTINTRODUCTION: JAK inhibitors (JAKis), used in the treatment of myelofibrosis, have entered standard treatment, providing significant improvements in spleen size and symptom burden. Although splenomegaly provides a reduction and some improvement in cytopenia, there is still a way to go. Novel JAKis are being investigated to overcome barriers to treatment access, such as therapeutic challenges, intolerance, and unresponsiveness.AREAS COVERED: This review includes the current status of JAKi treatment for myelofibrosis, ma...
Source: Expert Opinion on Investigational Drugs - October 9, 2023 Category: Drugs & Pharmacology Authors: Y ıldız I Pek Berkay K ılıç Ulgar Boran G ünay Ahmet Emre E şkazan Source Type: research
Bomedemstat as an investigative treatment for myeloproliferative neoplasms
Expert Opin Investig Drugs. 2023 Oct 7:1-8. doi: 10.1080/13543784.2023.2267980. Online ahead of print.ABSTRACTINTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic biology. Bomedemstat ...
Source: Expert Opinion on Investigational Drugs - October 7, 2023 Category: Drugs & Pharmacology Authors: Hugh Young Rienhoff Harinder Gill Source Type: research
Bomedemstat as an investigative treatment for myeloproliferative neoplasms
Expert Opin Investig Drugs. 2023 Oct 7. doi: 10.1080/13543784.2023.2267980. Online ahead of print.ABSTRACTINTRODUCTION: Myeloproliferative neoplasm (MPN) are heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but don't adequately address the underlying neoplastic biology. Bomedemstat has thus...
Source: Expert Opinion on Investigational Drugs - October 7, 2023 Category: Drugs & Pharmacology Authors: Hugh Young Rienhoff Harinder Gill Source Type: research
Investigational treatment strategies in glioblastoma: progress made and barriers to success
Expert Opin Investig Drugs. 2023 Oct 5. doi: 10.1080/13543784.2023.2267982. Online ahead of print.ABSTRACTINTRODUCTION: Glioblastoma, isocitrate dehydrogenase wildtype (IDHwt), remains an incurable disease despite considerable research effort. The current standard of care since 2005 comprises maximal safe resection followed by radiation with concurrent and adjuvant temozolomide; more recently, the addition of tumor treating fields was approved in the newly diagnosed and recurrent disease settings.AREAS COVERED: Searches of PubMed, Cochrane Library, and ClinicalTrials.gov provided a foundation for this review. We first desc...
Source: Expert Opinion on Investigational Drugs - October 5, 2023 Category: Drugs & Pharmacology Authors: Thomas A Nelson Jorg Dietrich Source Type: research
